NSMCE2 and gastric cancer: Accordingly, the GC cell line MGC803 was treated with erlotinib and shRNAs targeting BPTF, KLF5, or NUDT4 or overexpression plasmids of NSMCE2, EBNA1BP2, GTF3A, NXT1, or ADSL, and the efficacy of these plasmids or shRNAs in sensitizing GC cells to erlotinib was evaluated.